Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.


Options:
A: Inclusion Criteria:

* Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg
* Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction, stroke or TIA
* Intima-media thickness of the common carotid artery greater than or equal to 0.8 and less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl

Exclusion Criteria:

* Body mass index \> 30
* Any type of known secondary hypertension
* Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (\< 50/min)
* Obstructive pulmonary disease
* Claudicatio intermittens
* History or clinical evidence of any significant gastrointestinal, respiratory, hematological, metabolic, immunological or any other underlying disease which in the opinion of the investigator would interfere with the patient's participation in the trial
* Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy
* Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening
* Treatment with disallowed medication
* Pregnant or breastfeeding females or females of childbearing potential without adequate contraception
* History of alcohol and/or drug abuse
B: Inclusion Criteria:

* Written informed consent.
* Age\>18 years old.
* Negative serum pregnancy test (in women of childbearing only).
* Patients submitted to endovascular procedures below-the-knee by not exclusively.
* Patient understands and is willing and able to comply with the study instructions and follow-up visit.
* More than 70% stenosis or occlusion of the three distal arteries including or not the tibiofibular trunk (TFT).
* Tissue loss (Rutherford 5).
* One or more patent vessel of pedal arch.

Exclusion Criteria:

* TASC II D femoral and/or popliteal occlusion.
* Life expectancy less than 1 year.
* Allergy or contraindication to apixaban treatment.
* Allergy or contraindication to dual antiplatelet treatment.
* Creatinine clearance less than 30mL/min.
* Planned major amputation before procedure.
* Hybrid procedure (open and endovascular).
* Use of fibrinolytic in the past 10 days.
* Known HIV infection.
* Liver disease (acute or chronic hepatitis and cirrhosis).
* Drug addiction or alcohol abuse 12 months before the randomization.
* Concomitant medications thatinhibit the CYP 3A4 cytochrome and P glycoprotein (ketoconazole, Iitraconazole, ritonavir).
* Platelets count inferior to 100x109/L.
* INR more than 1.5.
* History or condition with high risk of bleeding: Eg. Trauma within 30 days before randomization, gastrointestinal bleeding 6 month before the randomization, intra-ocular, spinal, intra-articular bleeding (any time before), AV malformation, cerebral aneurysm and hypertension without control.
C: Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol between the 60th and 90th percentiles.
D: Inclusion Criteria:

* Patients with scheduled elective bariatric surgery or redo surgery after bariatric interventions
* Written informed consent

Exclusion Criteria:

* DVT and/or PE in the patient history
* Myocardial infarction, transient ischemic attack or stroke within 6 months of study entry
* Uncontrolled hypertension

Answer: C